Alnylam Pharmaceuticals (ALNY)
(Delayed Data from NSDQ)
$428.14 USD
+9.23 (2.20%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $425.98 -2.16 (-0.50%) 7:50 PM ET
3-Hold of 5 3
D Value F Growth B Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
ALNY 428.14 +9.23(2.20%)
Will ALNY be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ALNY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ALNY
Earnings Estimates Rising for Alnylam (ALNY): Will It Gain?
Are Medical Stocks Lagging ADC Therapeutics (ADCT) This Year?
ALNY: What are Zacks experts saying now?
Zacks Private Portfolio Services
ALNY Q2 Earnings Top Estimates on Higher Amvuttra Revenues, Stock Up
Alnylam (ALNY) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Alnylam Pharmaceuticals (ALNY) Q2 Earnings and Revenues Beat Estimates
Other News for ALNY
JPMorgan Boosts Alnylam (ALNY) Price Target Following Strong Q2 Performance
JP Morgan Raises ALNY Price Target to $475, Maintains Overweight Rating | ALNY Stock News
Alnylam price target raised by $127 at JPMorgan, here's why
Alnylam Pharmaceuticals Inc (ALNY) to Present at Canaccord Genuity 45th Annual Growth ...
Alnylam to Webcast Presentation at Canaccord Genuity 45th Annual Growth Conference | ALNY Stock News